Premium
Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: A multicenter study
Author(s) -
Jung WooYoung,
Kim SungGon,
Lee JinSeong,
Kang DongHo,
Jung BongJoo,
Shin DongHun,
Lee YoungMin,
Choi SangHeon
Publication year - 2015
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/pcn.12212
Subject(s) - ziprasidone , positive and negative syndrome scale , clinical global impression , akathisia , schizophrenia (object oriented programming) , rating scale , medicine , global assessment of functioning , psychology , brief psychiatric rating scale , depression (economics) , major depressive disorder , antipsychotic , montgomery–åsberg depression rating scale , psychiatry , psychosis , placebo , cognition , developmental psychology , alternative medicine , pathology , economics , macroeconomics
Aims The goal of this study was to examine the efficacy and safety of ziprasidone to treat depressive symptoms in K orean patients with schizophrenia who showed stable symptoms. Methods In this 8‐week, open‐label, prospective, non‐randomized, multicenter study, 34 patients with schizophrenia who showed a stable response to previous medications, maintained a stable dose, and who had depressive symptoms, were recruited. Ziprasidone was the only antipsychotic agent allowed for 8 weeks after a 2–7‐week washout period. Results Steady decreases were observed on the M ontgomery– A sberg D epression R ating S cale, the C algary D epression S cale for S chizophrenia, the P ositive and N egative S yndrome S cale, and the C linical G lobal I mpression‐ S everity S cale scores. The M ontgomery– A sberg D epression R ating S cale score was 20.26 ± 4.77 at baseline and 12.21 ± 7.94 at the end‐point ( P < 0.01). The C algary D epression S cale for S chizophrenia score was 9.76 ± 4.11 at baseline and 5.00 ± 3.94 at the end‐point ( P < 0.01). The P ositive and N egative S yndrome S cale total score was 75.24 ± 22.63 at baseline and 66.53 ± 24.28 at the end‐point ( P < 0.01). The C linical G lobal I mpression‐ S everity S cale score was 3.44 ± 0.66 at baseline and 3.15 ± 0.86 at the end‐point ( P < 0.05). No significant differences were observed for total scores on the S impson and A ngus R ating S cale, the B arnes A kathisia R ating S cale, or the A bnormal I nvoluntary M ovement S cale between the baseline and end‐point. Conclusions Ziprasidone was effective for improving depressive symptom scores and was well tolerated. Switching to ziprasidone is a good strategy in patients with schizophrenia who are experiencing depressive symptoms.